Inhibikase Therapeutics, Inc. Common Stock
Here’s whether Inhibikase Therapeutics, Inc. Common Stock (IKT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.14% over 10 days); strong 1-year return of +25.9%; 3-month momentum positive (+23.9%); rising volume confirms the move (1.30x 30d avg). Concerns: RSI 72 — overbought, elevated pullback risk. Currently 7.9% off its 52-week high. Score: +6/7.
IKT is in a confirmed uptrend, trading above both its 50-day ($1.86) and 200-day ($1.75) moving averages. With an RSI of 72.2, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +25.9% compares to +16.5% for SPY (beat the market by 9.5%).